Cargando…

hPG(80) (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors

SIMPLE SUMMARY: Current blood-based biomarkers for neuroendocrine neoplasms (NENs) lack both sensitivity and specificity. Human circulating progastrin (hPG(80)) can be easily measured in plasma by ELISA. This study is the first to examine hPG(80) in NENs. The study demonstrated increased levels of h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chauhan, Aman, Prieur, Alexandre, Kolesar, Jill, Arnold, Susanne, Payen, Léa, Mahi, Younes, Vire, Berengere, Sands, Madison, Evers, B. Mark, Joubert, Dominique, Anthony, Lowell
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870162/ https://www.ncbi.nlm.nih.gov/pubmed/35205614 http://dx.doi.org/10.3390/cancers14040863

Ejemplares similares

Prognostic Value of Plasma hPG(80) (Circulating Progastrin) in Metastatic Renal Cell Carcinoma
por: Kohli, Manish, et al.
Publicado: (2021)

Plasma hPG(80) (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort
por: Prieur, Alexandre, et al.
Publicado: (2023)

The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients
por: You, Benoit, et al.
Publicado: (2019)

hPG(80) (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot study
por: Casile, Melanie, et al.
Publicado: (2023)

Association between post-operative hPG(80) (circulating progastrin) detectable level and worse prognosis in glioblastoma
por: Doucet, L., et al.
Publicado: (2023)

Plasma hPG(80) (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma
por: Dupuy, Marie, et al.
Publicado: (2022)

Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status
por: Chauhan, Aman, et al.
Publicado: (2018)

Gynecologic large cell neuroendocrine carcinoma: A review
por: Burkeen, Grant, et al.
Publicado: (2020)

The Family Biorhythm: Contributions of the HPA and HPG Axes to Neuroendocrine Attunement
por: Wood, Erin E., et al.
Publicado: (2023)

Inactivation of the lysine binding sites of human plasminogen (hPg) reveals novel structural requirements for the tight hPg conformation, M-protein binding, and rapid activation
por: Ayinuola, Yetunde A., et al.
Publicado: (2023)

Biliary tract large cell neuroendocrine carcinoma: current evidence
por: Raiker, Riva, et al.
Publicado: (2019)

Management of Large Cell Neuroendocrine Carcinoma
por: Corbett, Virginia, et al.
Publicado: (2021)

Clinical significance of progastrin-releasing peptide, neuron-specific enolase, chromogranin a, and squamous cell cancer antigen in pulmonary neuroendocrine tumors
por: TUTAR, Nuri, et al.
Publicado: (2019)

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary
por: Chauhan, Aman, et al.
Publicado: (2018)

Global burden of neuroendocrine tumors and changing incidence in Kentucky
por: Chauhan, Aman, et al.
Publicado: (2018)

Immune checkpoint inhibitors in neuroendocrine tumors: A single institution experience with review of literature
por: Chauhan, Aman, et al.
Publicado: (2017)

Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population
por: Guo, Wen, et al.
Publicado: (2018)

The Effect of the Extent of Neuroendocrine Differentiation on Cytopathological Findings in Primary Neuroendocrine Neoplasms of the Breast
por: Guzelbey, Burcu, et al.
Publicado: (2021)

Moderately Differentiated Neuroendocrine Carcinoma of the Larynx
por: Chung, Eun-Jae, et al.
Publicado: (2008)

Unusual apocrine carcinoma with neuroendocrine differentiation: a cutaneous neoplasm may be analogous to neuroendocrine carcinoma with apocrine differentiation of breast
por: Li, Yang, et al.
Publicado: (2015)

Differential expression and tumorigenic function of neurotensin receptor 1 in neuroendocrine tumor cells
por: Kim, Ji Tae, et al.
Publicado: (2015)

Prostate cancer with neuroendocrine differentiation – case report
por: Glück, G, et al.
Publicado: (2012)

Neuroendocrine differentiation in a case of cervical cancer
por: Mona Mohamed, Rashed, et al.
Publicado: (2010)

Dermatomyositis associated with prostate adenocarcinoma with neuroendocrine differentiation
por: Minagawa, Hideyuki, et al.
Publicado: (2021)

Primary Well-Differentiated Neuroendocrine Tumor of the Kidney
por: Prasad, Vishnu, et al.
Publicado: (2023)

Neuroendocrine Tumors in Pediatrics
por: Farooqui, Zainab Azam, et al.
Publicado: (2019)

Is neuroendocrine differentiation a prognostic factor in poorly differentiated colorectal cancer?
por: Chen, Yue, et al.
Publicado: (2017)

Tumor Microenvironment in Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: Interaction between Tumors and Immune Cells, and Potential Effects of Neuroendocrine Differentiation on the Tumor Microenvironment
por: Tsunokake, Junichi, et al.
Publicado: (2022)

Targeting progastrin enhances radiosensitization of colorectal cancer cells
por: Kowalski-Chauvel, Aline, et al.
Publicado: (2017)

Pulmonary Neuroendocrine Cells and Small Cell Lung Carcinoma: Immunohistochemical Study Focusing on Mechanisms of Neuroendocrine Differentiation
por: Ito, Takaaki, et al.
Publicado: (2022)

Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors
por: Thiis‐Evensen, Espen, et al.
Publicado: (2022)

Integrating a 92-Gene Expression Analysis for the Management of Neuroendocrine Tumors of Unknown Primary
por: Chauhan, Aman, et al.
Publicado: (2019)

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
por: Mitry, E, et al.
Publicado: (1999)

Neuroendocrine Differentiation of Primary Mucinous Carcinoma of the Cheek Skin
por: Han, So-Eun, et al.
Publicado: (2013)

The Many Faces of Neuroendocrine Differentiation in Prostate Cancer Progression
por: Terry, Stéphane, et al.
Publicado: (2014)

SIRT1 contributes to neuroendocrine differentiation of prostate cancer
por: Ruan, Lin, et al.
Publicado: (2017)

FOXA1 inhibits prostate cancer neuroendocrine differentiation
por: Kim, Jung, et al.
Publicado: (2017)

Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors
por: Pusceddu, Sara, et al.
Publicado: (2020)

Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms
por: Hofland, Johannes, et al.
Publicado: (2020)

Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression
por: Xie, Yuchen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_magr2js8fj0dan32gigluam6mc